drugset / Trial / NCT05528367
Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NaSingle-groupOpen-labelPrevention
Summary
To evaluate the efficacy and safety of chemoradiotherapy combined with tirelizumab in the treatment of initial unresectable locally advanced gastric cancer or gastroesophageal junction cancer.
Timeline
- Start
- 2022-01-01
- Primary completion
- 2024-06-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-PTX | Unknown | 100 mg/m2 | — |
| Subject | Nab-PTX | Unknown | 100 mg | — |
| Subject | Nab-PTX | Unknown | 130 mg/m2 | — |
| Subject | S-1 | Small molecule | 80 mg | — |
| Subject | S-1 | Small molecule | 100 mg | — |
| Subject | S-1 | Small molecule | 120 mg | — |
| Subject | Tirelizumab | Monoclonal antibody | 200 mg | — |